ES2634137T3 - Diagnóstico y estratificación del riesgo de infecciones y enfermedades crónicas de las vías respiratorias y los pulmones por medio de provasopresina, en particular copeptina o neurofisina II - Google Patents
Diagnóstico y estratificación del riesgo de infecciones y enfermedades crónicas de las vías respiratorias y los pulmones por medio de provasopresina, en particular copeptina o neurofisina II Download PDFInfo
- Publication number
- ES2634137T3 ES2634137T3 ES11170807.9T ES11170807T ES2634137T3 ES 2634137 T3 ES2634137 T3 ES 2634137T3 ES 11170807 T ES11170807 T ES 11170807T ES 2634137 T3 ES2634137 T3 ES 2634137T3
- Authority
- ES
- Spain
- Prior art keywords
- copeptin
- patients
- infections
- provasopressin
- chronic diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101800000115 Copeptin Proteins 0.000 title abstract description 25
- 208000017667 Chronic Disease Diseases 0.000 title abstract description 3
- 208000015181 infectious disease Diseases 0.000 title abstract description 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 title abstract 2
- 210000004072 lung Anatomy 0.000 title description 4
- 102000002710 Neurophysins Human genes 0.000 title description 2
- 108010018674 Neurophysins Proteins 0.000 title description 2
- 238000003745 diagnosis Methods 0.000 title description 2
- 210000002345 respiratory system Anatomy 0.000 title description 2
- 238000013517 stratification Methods 0.000 title description 2
- 238000001514 detection method Methods 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 abstract description 2
- 108010064409 proAVP hormone Proteins 0.000 abstract description 2
- 208000032376 Lung infection Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 102400000060 Copeptin Human genes 0.000 description 23
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010091794 preprovasopressin Proteins 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006053442A DE102006053442A1 (de) | 2006-11-12 | 2006-11-12 | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006053442 | 2006-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2634137T3 true ES2634137T3 (es) | 2017-09-26 |
Family
ID=39277664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11170807.9T Active ES2634137T3 (es) | 2006-11-12 | 2007-11-11 | Diagnóstico y estratificación del riesgo de infecciones y enfermedades crónicas de las vías respiratorias y los pulmones por medio de provasopresina, en particular copeptina o neurofisina II |
| ES07846321T Active ES2370071T3 (es) | 2006-11-12 | 2007-11-11 | Diagnóstico y estratificación del riesgo de infecciones y enfermedades crónicas de las vías respiratorias y los pulmones por medio de provasopresina, en particular copeptina o neurofisina ii. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07846321T Active ES2370071T3 (es) | 2006-11-12 | 2007-11-11 | Diagnóstico y estratificación del riesgo de infecciones y enfermedades crónicas de las vías respiratorias y los pulmones por medio de provasopresina, en particular copeptina o neurofisina ii. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8158368B2 (enExample) |
| EP (2) | EP2089718B1 (enExample) |
| JP (3) | JP5340160B2 (enExample) |
| CN (2) | CN105092858A (enExample) |
| AT (1) | ATE522814T1 (enExample) |
| DE (1) | DE102006053442A1 (enExample) |
| DK (1) | DK2378290T3 (enExample) |
| ES (2) | ES2634137T3 (enExample) |
| HK (1) | HK1215731A1 (enExample) |
| WO (1) | WO2008058517A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| ES2652027T3 (es) | 2006-10-26 | 2018-01-31 | B.R.A.H.M.S. Gmbh | Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| US20120329666A1 (en) * | 2009-10-05 | 2012-12-27 | Duke University | Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use |
| EP2776064A4 (en) | 2011-11-11 | 2015-08-05 | Woomera Therapeutics | ANTAGONISTS OF PRO-VASOPRESSIN AND USES THEREOF |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| WO2023191145A1 (ko) | 2022-03-31 | 2023-10-05 | (주)네오닉스 | 배터리팩 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| DE10027954A1 (de) | 1999-12-22 | 2001-06-28 | Dade Behring Marburg Gmbh | Humanes Procalcitonin, dessen Herstellung und Verwendung |
| ES2280170T3 (es) | 1999-12-22 | 2007-09-16 | Dade Behring Marburg Gmbh | Soluciones de procalcitonina humana. |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| JP2006505510A (ja) * | 2002-07-16 | 2006-02-16 | ウーメラ セラピューティックス， インク． | プロバソプレシン発現癌細胞の同定および治療のための組成物およびその利用 |
| AU2003302340B8 (en) * | 2002-12-24 | 2008-09-11 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| EP1628136A1 (en) | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102004047968A1 (de) * | 2004-10-01 | 2006-04-06 | B.R.A.H.M.S Ag | Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen |
| GB0508863D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Peptide |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| JP4983525B2 (ja) * | 2007-10-11 | 2012-07-25 | 住友電装株式会社 | ワイヤハーネスのプロテクタ取付構造 |
| US9229013B2 (en) * | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
-
2006
- 2006-11-12 DE DE102006053442A patent/DE102006053442A1/de not_active Withdrawn
-
2007
- 2007-11-11 DK DK11170807.9T patent/DK2378290T3/en active
- 2007-11-11 EP EP07846321A patent/EP2089718B1/de active Active
- 2007-11-11 EP EP11170807.9A patent/EP2378290B1/de active Active
- 2007-11-11 CN CN201510454116.7A patent/CN105092858A/zh active Pending
- 2007-11-11 ES ES11170807.9T patent/ES2634137T3/es active Active
- 2007-11-11 US US12/514,524 patent/US8158368B2/en active Active
- 2007-11-11 CN CNA2007800420148A patent/CN101563613A/zh active Pending
- 2007-11-11 JP JP2009535559A patent/JP5340160B2/ja active Active
- 2007-11-11 AT AT07846321T patent/ATE522814T1/de active
- 2007-11-11 WO PCT/DE2007/002037 patent/WO2008058517A2/de not_active Ceased
- 2007-11-11 ES ES07846321T patent/ES2370071T3/es active Active
-
2012
- 2012-03-21 US US13/425,928 patent/US20120270245A1/en not_active Abandoned
-
2013
- 2013-01-04 JP JP2013000176A patent/JP2013083664A/ja active Pending
-
2015
- 2015-07-31 JP JP2015151852A patent/JP6170101B2/ja active Active
-
2016
- 2016-03-30 HK HK16103639.3A patent/HK1215731A1/zh unknown
- 2016-06-13 US US15/180,797 patent/US10718783B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10718783B2 (en) | 2020-07-21 |
| WO2008058517A2 (de) | 2008-05-22 |
| WO2008058517A3 (de) | 2008-10-23 |
| US20170059583A1 (en) | 2017-03-02 |
| CN105092858A (zh) | 2015-11-25 |
| JP5340160B2 (ja) | 2013-11-13 |
| ES2370071T3 (es) | 2011-12-12 |
| EP2378290B1 (de) | 2017-05-03 |
| ATE522814T1 (de) | 2011-09-15 |
| US20120270245A1 (en) | 2012-10-25 |
| JP6170101B2 (ja) | 2017-07-26 |
| DE102006053442A1 (de) | 2008-05-15 |
| US8158368B2 (en) | 2012-04-17 |
| DK2378290T3 (en) | 2017-07-31 |
| JP2016026286A (ja) | 2016-02-12 |
| EP2089718A2 (de) | 2009-08-19 |
| HK1215731A1 (zh) | 2016-09-09 |
| JP2010509576A (ja) | 2010-03-25 |
| CN101563613A (zh) | 2009-10-21 |
| EP2378290A1 (de) | 2011-10-19 |
| EP2089718B1 (de) | 2011-08-31 |
| JP2013083664A (ja) | 2013-05-09 |
| US20100041064A1 (en) | 2010-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2634137T3 (es) | Diagnóstico y estratificación del riesgo de infecciones y enfermedades crónicas de las vías respiratorias y los pulmones por medio de provasopresina, en particular copeptina o neurofisina II | |
| ES2401703T3 (es) | Utilización de la procalcitonina (PCT) en la estratificación de riesgo y el pronóstico de los pacientes con una enfermedad primaria no infecciosa | |
| ES2631653T3 (es) | Predicción del desenlace en pacientes con enfermedad pulmonar obstructiva crónica | |
| ES2369977T3 (es) | Utilización de la procalcitonina (pct) en la estratificación de riesgo y el pronóstico de los pacientes con una enfermedad primaria no infecciosa. | |
| ES2388055T3 (es) | Diagnóstico y estratificación de riesgo mediante NT-proET-1 | |
| ES2380440T3 (es) | Marcador para fallo de injerto y mortalidad | |
| ES2944613T3 (es) | proADM y/o histonas como marcadores indicadores de un acontecimiento adverso | |
| Seligman et al. | Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia | |
| ES2617982T3 (es) | Procalcitonina para la prognosis de eventos adversos | |
| Lorente et al. | High serum nitrates levels in non-survivor COVID-19 patients | |
| Christ-Crain et al. | Procalcitonin and pneumonia: is it a useful marker? | |
| Kerbaul et al. | High concentrations of N-BNP are related to non-infectious severe SIRS associated with cardiovascular dysfunction occurring after off-pump coronary artery surgery | |
| Contrera Rolón et al. | Characteristics of acute kidney injury in adult patients with severe COVID-19. | |
| Gille et al. | Evaluation of MR-proANP and copeptin for sepsis diagnosis after burn injury | |
| Liu et al. | Pathogen burden in essential hypertension | |
| US11592450B2 (en) | Diagnosis and risk stratification of fungal infections | |
| US20240255531A1 (en) | Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients | |
| Asha et al. | The association of hematological and biochemical parameters with mortality among COVID-19 patients: A retrospective study from north India | |
| Özkarafakılı et al. | Could Asymmetric Dimethylarginine Have a Role in COVID-19 Cases? | |
| Elnagar et al. | Red Blood Cell Distribution Width Level as Reliable Diagnostic and Prognostic Biomarker in Septic Patients: A Case-Control Study | |
| Sadeq et al. | Role of Oxidative Stress in Pathogenesis and Severity of COVID-19 Infection: Case-Control Study in Iraq | |
| Ahmed Abd EL Hai et al. | Assessment the Value of Serum Copeptin Level in Dilated Cardiomyopathy in Pediatrics | |
| Kardol-Hoefnagel et al. | Clara cell 16 kDa protein: an important marker for COVID-19 severity | |
| HK1135183A (en) | Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin ii | |
| Prajwal | Study of Clinical and Radiological Profile of Community Aquired Pneumonia with Special Reference to C-Reactive Protien and Procalcitonin Levels |